Your browser doesn't support javascript.
A Houttuynia cordata-based Chinese herbal formula improved symptoms of allergic rhinitis during the COVID-19 pandemic.
Chang, Kai-Wei; Lin, Tung-Yi; Fu, Shu-Ling; Ping, Yueh-Hsin; Chen, Fang-Pey; Kung, Yen-Ying.
  • Chang KW; Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
  • Lin TY; Center for Traditional Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Fu SL; Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
  • Ping YH; Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
  • Chen FP; Department of Pharmacology, School of Medicine and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
  • Kung YY; Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
J Chin Med Assoc ; 85(6): 717-722, 2022 06 01.
Article in English | MEDLINE | ID: covidwho-2037568
ABSTRACT

BACKGROUND:

The symptoms of coronavirus disease 2019 (COVID-19) such as hyposmia, rhinorrhea, nasal obstruction, and cough are similar to those of chronic allergic rhinitis (AR). Such symptoms can easily lead AR patients to unnecessary anxiety, misdiagnosis, and invasive diagnostic tests in the COVID-19 pandemic. Interleukin-6 (IL-6) is an important mediator for chronic AR and plays a crucial role in the inflammation of COVID-19. Houttuynia cordata (HC) has been shown to reduce nasal congestion and swelling by suppressing the activation of IL-6 and is used to fight COVID-19. A novel HC-based Chinese herbal formula, Zheng-Yi-Fang (ZYF), was developed to test effects on nasal symptoms of patients with AR in the COVID-19 pandemic.

METHODS:

Participants aged between 20 and 60 years with at least a 2-year history of moderate to severe perennial AR were enrolled. Eligible participants were randomly allocated to either the intervention group (taking ZYF) or the control group (using regular western medicine) for 4 weeks. The Chinese version of the Rhinosinusitis Outcome Measures was used to evaluate impacts on quality of life and nasal symptoms of participants with AR. In addition, the effect of ZYF on lipopolysaccharide (LPS)-induced IL-6 was investigated.

RESULTS:

Participants with AR taking ZYF improved their symptoms of nasal obstruction, nasal secretion, hyposmia, and postnasal drip in comparison with those of the control group. Meanwhile, ZYF exhibited inhibition of IL-6 secretion in the LPS-induced inflammatory model.

CONCLUSION:

ZYF has potential effects to relieve nasal symptoms for AR during the COVID-19 pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drugs, Chinese Herbal / Houttuynia / Rhinitis, Allergic Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Adult / Humans / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: J Chin Med Assoc Journal subject: Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Drugs, Chinese Herbal / Houttuynia / Rhinitis, Allergic Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Adult / Humans / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: J Chin Med Assoc Journal subject: Medicine Year: 2022 Document Type: Article